34 results about "Alanine transaminase" patented technology

The invention belongs to the technical field of health-care products, food and medicine and discloses a blood-fat reducing composition and an application thereof. The composition comprises ornithine, aspartate and vitamin B6. The blood-fat reducing composition can adjust blood-fat, protect the liver, enhance the blood supply capacity of heart and cerebral vessels, lower triglyceride and cholesterol, improve the enzyme activity of alanine transaminase and glutamic-oxaloacetic transaminase, promote fatty acid metabolism, and recover the blood-fat reducing ability of the body; the blood-fat reducing composition can be used for preparing the medicine for reducing the blood fat, the health-care products, food additives or the food.

The invention relates to a compound medicament for treating a chronic liver disease and a preparation method thereof. The compound medicament is prepared from artemisia capillaries, artemisia rupestris, cichorium glandulosum boiss et huet, rose, rhubarb and licorice which are used as raw materials and medicinal accessories and prepared into an oral preparation, syrup granules, hard capsules and tablets by adopting a method of solvent extraction, impurity removal, concentration and drying. The active ingredients in the compound medicament are dissolved by adopting a reasonable extraction method according to the Uyghur medicinal theory, the characteristics of national medicine and the long-term folk clinical practice of the Uyghur nationality, so that the medicinal effects are enhanced, and the bioavailability is improved. Animal experiments prove that the compound medicament has a protective effect on liver injury. Pharmacodynamic experiments show that the extract obtained by the method can inordinately reduce the alanine transaminase (ALT) and aspartate transferase (AST) levels in mouse serum of a liver injury model, the pathological symptoms in each medication administration team are relieved, and the liver injury is protected. Acute toxicity experiments show that the maximum dosage of the extract obtained by the method is equivalent to 337 folds of clinical human proposed dosage according to mouse intragastric single-time administration toxicity test, and the extract is nontoxic and safe.

A novel alanine aminotransferase gene (ALT2) has been isolated from human tissues, and ALT2-specific nucleic acids, proteins and antibodies thereof have been described above. ALT2 is mainly expressed in liver, kidney, brain, muscle and adipose tissue. ALT2 can be used as a diagnosis of damage and disease of ALT2-producing tissues.

The invention discloses a method for preparing alanine aminotransferase, which includes the following steps: modifying a whole-genome-synthesized humanized alanine aminotransferase encoding gene sequence, and removing rare codons of escherichia coli; inserting the modified alanine aminotransferase encoding gene sequence into an expression vector, and adopting bacterial strains of escherichia coli for transformation and expression; inoculating the transformed and expressed bacterial strains with an LB culture medium and performing IPTG (isopropyl-Beta-d-thiogalactoside) induction; and breaking the obtained thalli, performing centrifugal separation, and passing by the Ni-NTA columns for purification. The operation for preparing alanine aminotransferase is very simple, the preparation cost is low, the product yield is high, the purity is high, and high biological activity is obtained; the prepared alanine aminotransferase serving as antigenic substances can be used for animal immunization, related antibodies can be screened; and meanwhile, the method lays the foundation of quick establishment for a calibrator preparing platform imperative to the domestic clinical chemistry diagnosis as well as development and preparation for diagnostic reagent standard substances and references.

The invention relates to a corynebacterium glutamicum recombinant bacterium for enhancing effective utilization of pyruvic acid and improving the yield of leucine and a construction method of the corynebacterium glutamicum recombinant bacterium, and belongs to the field of gene engineering. According to the invention, a genetic engineering method is applied to knock out a pyruvate carboxylase genepyc participating in an intracellular oxaloacetic acid supplementing pathway and an alanine transaminase gene avtA participating in alanine synthesis in corynebacterium glutamicum; meanwhile, in order to weaken synthesis capacity of alanine in a competing branch, a T3 terminator is added in front of an alaT gene to weaken the expression level of the alaT gene, so that effective utilization of recombinant bacterial intracellular pyruvic acid is realized, and the recombinant corynebacterium glutamicum with an improved L-leucine yield is obtained. The leucine yield of the recombinant corynebacterium glutamicum is increased by 15.3% compared with an original strain. According to the invention, utilization of pyruvic acid is successfully strengthened, the synthetic flux of pyruvic acid to L-leucine is improved, and a new idea is provided for breeding pyruvic acid amino acid high-yield bacteria.

The invention relates to a recombinant bacterium of Corynebacterium glutamicum capable of enhancing the effective utilization of pyruvate and increasing the yield of leucine and a construction method thereof, belonging to the field of genetic engineering. The present invention applies the genetic engineering method to knock out the pyruvate carboxylase gene pyc and the alanine aminotransferase gene avtA involved in the synthesis of alanine in Corynebacterium glutamicum, which participate in the intracellular oxaloacetate replenishment pathway; The alanine synthesis ability of the branch, adding a T3 terminator before the alaT gene weakens its expression level, realizes the effective utilization of pyruvate in the recombinant bacteria, and obtains the recombinant Corynebacterium glutamicum with improved L-leucine production. The leucine yield of the recombinant Corynebacterium glutamicum is 15.3% higher than that of the starting strain. This invention successfully strengthens the utilization of pyruvate and improves the synthesis flux from pyruvate to L-leucine, which also provides a new idea for breeding high-yielding bacteria of pyruvate family amino acids.

The invention discloses an application of methane injection in preparation of medicaments for treating ischemia-reperfusion injury, which comprises a preparation method of the methane injection. Animal experiments are performed on the methane injection, and the results prove that the methane injection can be used for obviously reducing the level of alanine transaminase, reducing liver injury and reducing hepatocyte apoptosis against a rat model with liver ischemia-reperfusion injury, so that the methane injection can be used for treating the liver ischemia-reperfusion injury. Thus, the methane injection disclosed by the invention can be used for preparing the medicaments for treating the ischemia-reperfusion injury.

The invention discloses a method for quantitatively detecting alanine transaminase in a solution based on a copper nanocluster fluorescent probe, wherein a copper nanocluster with glutathione as a protective agent is used as a fluorescent probe, and the content of alanine transaminase in the solution is specifically detected through a fluorescence "off-on" mode. The label-free, highly sensitive and selective detection of alanine transaminase is achieved by adopting the fluorescence "off-on" mode. The method is simple and rapid, the specific detection of alanine transaminase can be realized, the detection linear range is wide, and the detection limit is low. The method in the invention has good detection sensitivity and selectivity and has good application prospects in disease detection, clinical application and other aspects.

An Alpha-oxoglutarate content measurement kit comprises a box main body, a cover plate, a rotation shaft and a fixed seat. A detection method comprises the steps of sample preparation, in which a sample is taken, PH7.8 phosphate buffer liquid is added for grinding, centrifugation is performed for 10 minutes, a supernatant liquid is waited for measurement; detection step, in which the detection step comprises the steps of 1, pre-heating by a photometer, and performing zero setting with distilled water; 2, adding a standard point, alanine, NAD+, glutamate dehydrogenase, 2-(4-iodobenzene)-3-(4-nitrobenzene)-5-(thiobenzoate)-2H-tetrazolium salt, a phosphate buffer liquid and alanine aminotransferase into a standard measurement pipe, adding alanine, NAD+, glutamate dehydrogenase, 2-(4-iodobenzene)-3-(4-nitrobenzene)-5-(thiobenzoate)-2H-tetrazolium salt, a phosphate buffer liquid and alanine transaminase into a blank pipe, adding the to-be-measured supernatant liquid and then adding constituents in the blank pipe into a sample measurement pipe, and adding the to-be-measured supernatant liquid, NAD+, glutamate dehydrogenase, L2-(4-iodobenzene)-3-(4-nitrobenzene)-5-(thiobenzoate)-2H-tetrazolium salt and a phosphate buffer liquid into a contrast pipe; and 3, immediately and uniformly mixing, reacting for 30 min, transferring to a glass cell, reading a light absorption value A of each pipe, and calculating Alpha-oxoglutarate(Alpha-KG) content according to sample mass. The method is simple and easy to operate.

The invention relates to the technical field of biology and in particular relates to a method for constructing a hepatitis B virus (HBV) infected mouse model and application of the HBV infected mouse model. The invention provides a method for constructing a high-ALT (alanine transaminase) HBV infected mouse model. The method for constructing the HBV infected mouse model comprises the step of medicating HBV genome DNA plasmid to a Tlr2 gene-deficient mouse, so that the HBV infected mouse model is constructed. The mouse model provided by the invention is relatively simple to construct, relatively easy in technological means and low in construction cost; besides, the adopted HBV plasmid vector is non-toxic, can not induce immune response of the mouse and also can avoid serious immunodeficiency in a chimera mouse model, and the obtained HBV infected model has higher blood serum ALT level and obvious liver inflammation expression.

Novel alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and / or tissue malfunction. The ALT polypeptides are murine and / or rattus ALT polypeptides and said ALT polypeptides are used to detect, predict and / or determine hepatic processes of an animal, particularly mice and / or rats.

The invention discloses a construction method of Escherichia coli with high yield of L-tryptophan and low yield of L-alanine, which comprises the following steps: respectively designing knockout primer pairs with homologous arms according to sequence information of alaA and alaC in E.coli K-12 alanine transaminase genes of the E.coli K-12 alanine transaminase genes, and knockout amino transferase genes alaA and alaC to obtain L-tryptophan with high yield and low yield of L-alanine. The recombinant escherichia coli can more fully utilize the carbon metabolic flow to synthesize the L-tryptophan, so that the yield of the L-tryptophan is increased, the yield of an L-alanine by-product in a metabolic pathway of the escherichia coli is reduced, and the pressure of product purification is relieved.

The invention relates to a compound medicament for treating a chronic liver disease and a preparation method thereof. The compound medicament is prepared from artemisia capillaries, artemisia rupestris, cichorium glandulosum boiss et huet, rose, rhubarb and licorice which are used as raw materials and medicinal accessories and prepared into an oral preparation, syrup granules, hard capsules and tablets by adopting a method of solvent extraction, impurity removal, concentration and drying. The active ingredients in the compound medicament are dissolved by adopting a reasonable extraction method according to the Uyghur medicinal theory, the characteristics of national medicine and the long-term folk clinical practice of the Uyghur nationality, so that the medicinal effects are enhanced, and the bioavailability is improved. Animal experiments prove that the compound medicament has a protective effect on liver injury. Pharmacodynamic experiments show that the extract obtained by the method can inordinately reduce the alanine transaminase (ALT) and aspartate transferase (AST) levels in mouse serum of a liver injury model, the pathological symptoms in each medication administration team are relieved, and the liver injury is protected. Acute toxicity experiments show that the maximum dosage of the extract obtained by the method is equivalent to 337 folds of clinical human proposed dosage according to mouse intragastric single-time administration toxicity test, and the extract is nontoxic and safe.

The invention relates to an application of a medicine composition in preparation of medicines for preventing or treating fatty liver. The medicine composition is mainly composed of the six traditional Chinese medicines including astragalus membranaceus, glossy privet fruit, leech, rheum officinale, radix pseudostellariae and barbary wolfberry fruit. The medicine composition has the functions of reducing the index values of serum triglyceride (TG), total cholesterol (TCH), TG (triglyceride) in liver tissues and the like in a fatty liver model, increasing the index values of high-density lipoprotein (HDL) in serum and the like, and reducing the index values of alanine aminotransferase (ALT), malondialdehyde (MDA), glutathione (GSH) and the like in the liver tissues. Simultaneously, the medicine composition is further capable of reducing the degrees of the vacuolar degeneration, debonding degeneration, fatty degeneration, diffuse tissue necrosis and inflammatory cell diffuse infiltration of liver tissues in the fatty liver models of rats and mice. The results prove that the medicine composition has a definite curative effect on fatty liver.

The invention relates to an application of a medicine composition in preparation of medicines for preventing or treating fatty liver. The medicine composition is mainly composed of the six traditional Chinese medicines including astragalus membranaceus, glossy privet fruit, leech, rheum officinale, radix pseudostellariae and barbary wolfberry fruit. The medicine composition has the functions of reducing the index values of serum triglyceride (TG), total cholesterol (TCH), TG (triglyceride) in liver tissues and the like in a fatty liver model, increasing the index values of high-density lipoprotein (HDL) in serum and the like, and reducing the index values of alanine aminotransferase (ALT), malondialdehyde (MDA), glutathione (GSH) and the like in the liver tissues. Simultaneously, the medicine composition is further capable of reducing the degrees of the vacuolar degeneration, debonding degeneration, fatty degeneration, diffuse tissue necrosis and inflammatory cell diffuse infiltration of liver tissues in the fatty liver models of rats and mice. The results prove that the medicine composition has a definite curative effect on fatty liver.